Treatment and Prognosis of Osteoarthritis Patients in China: a Multicentre, Large Scale, Real World Study
J. Peng,X. Zhang,L. Ren,J. Huang,G. Ning,Z. Gao,D. Zhao,X. Fu,Z. Wang,S. Wang,M. Yang,W. Xiao,L. Lin,Y. Xue,J. Luo,D. Tang,A. Huang,X. Chen,J. Feng,F. Zhao,J. Li,Q. Wang,Y. Zhou,Z. Li
DOI: https://doi.org/10.1016/j.joca.2020.02.600
IF: 7.507
2020-01-01
Osteoarthritis and Cartilage
Abstract:Purpose: To evaluate the clinical characteristics, therapy and prognosis of osteoarthritis (OA) patients in China. Methods: A cross-sectional, multicentre, real world study was conducted in 64 hospitals from June 2018 to April 2019. A consecutive sample of 2419 with OA was recruited. Socio-demographic information, clinical characteristics, and medical conditions were collected. The data were analysed by descriptive analysis, independent sample T test and multivariate linear regression analysis. Results: Among subjects (66% female; mean age 61.44±10.65 years) included in this analysis, 57.0% (1378/2419) of patients took disease modifying osteoarthritis drugs (DMOADs). 55.6% (1346/2419) of patients took non-steroid anti-inflammatory drugs (NSAIDs) and analgesics. 20.7% (500/2419) had intra-articular injections. Other treatments included topical drugs (38.0%), braces (6.8%) and surgery (3.5%). Compared those who never used DMOADs in 2055 knee OA and/or hip OA patients, patients who used DMOADs had higher scores in total score (P<0.001), pain (P=0.005), stiffness (P=0.009) and function (P<0.001) with The Western Ontario and McMaster Universities (WOMAC) osteoarthritis index. However, in multivariate linear regression analysis models, there was no significant difference between DMOADs subgroup and non-DMOADs subgroup. The older age of knee OA and hip OA patients was associated with higher scores in WOMAC pain (β=0.036, P=0.002), WOMAC function (β=0.161, P=0.000), sleeping-visual analogue scale (VAS)(β=0.040, P=0.000), Hospital Anxiety and Depression Scale (HAD)-anxiety (β=0.038, P=0.006) and HAD-depression (β=0.087, P=0.000). Longer duration of knee and hip OA was associated with higher scores in WOMAC pain (β=0.053, P=0.022). Among 762 hand OA patients, longer duration of hand OA was associated with higher scores in AUSCAN (β=0.399, P=0.000), AUSCAN function (β=0.287, P=0.000), and Modified Health Assessment Questionnaire (mHAQ) (β=0.120, P=0.028). Conclusions: The mainly treatment of OA are taking DMOADs and NSAIDs. Patients with more severe illness are more likely to take DMOADs. Longer duration and older age are associated with higher disease activity.